181261-73-4 Usage
Description
4,5,6-TRICHLORONICOTINIC ACID ETHYL ESTER, with the chemical formula C8H5Cl3NO2, is an organic compound that functions as a potent herbicide and pesticide. Its ester form enhances solubility in organic solvents and stability, making it a more effective agent for agricultural use. However, its toxicity to humans and potential harm to the environment necessitate careful handling and responsible use.
Uses
Used in Agricultural Industry:
4,5,6-TRICHLORONICOTINIC ACID ETHYL ESTER is used as a herbicidal and pesticidal agent for controlling the growth of unwanted plants and fungi. Its application reason lies in its ability to inhibit the growth of these organisms, thereby protecting crops and enhancing agricultural productivity.
Used in Pest Control:
In the pest control sector, 4,5,6-TRICHLORONICOTINIC ACID ETHYL ESTER is used as a chemical treatment to manage and eliminate pests that can damage crops and reduce yields. Its effectiveness in controlling a broad spectrum of pests makes it a valuable tool in integrated pest management strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 181261-73-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,2,6 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 181261-73:
(8*1)+(7*8)+(6*1)+(5*2)+(4*6)+(3*1)+(2*7)+(1*3)=124
124 % 10 = 4
So 181261-73-4 is a valid CAS Registry Number.
181261-73-4Relevant articles and documents
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1h)-ones
Wallace, Eli M.,Lyssikatos, Joseph,Blake, James F.,Seo, Jeongbeob,Yang, Hong Woon,Yeh, Tammie C.,Perrier, Michele,Jarski, Heidi,Marsh, Vivienne,Poch, Gregory,Livingston, Michelle Goyette,Otten, Jennifer,Hingorani, Gary,Woessner, Rich,Lee, Patrice,Winkler, James,Koch, Kevin
, p. 441 - 444 (2007/10/03)
The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.
